| scholarly article | Q13442814 |
| P50 | author | Michael Green | Q89739732 |
| P2093 | author name string | Ravinder Anand | |
| Wanrong Yin | |||
| George Mazariegos | |||
| Michael Millis | |||
| Michael R Narkewicz | |||
| Stephen Dunn | |||
| Studies of Pediatric Liver Transplantation Research Group | |||
| Susan McDiarmid | |||
| P2860 | cites work | The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders | Q33293373 |
| Epstein-Barr virus and post-transplant lymphoproliferative disease | Q35009613 | ||
| Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment | Q35108227 | ||
| Risk factors for rejection and infection in pediatric liver transplantation | Q37045877 | ||
| History of pediatric liver transplantation. Where are we coming from? Where do we stand? | Q39221296 | ||
| Studies of Pediatric Liver Transplantation (SPLIT): year 2000 outcomes | Q40691813 | ||
| The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children | Q41453710 | ||
| Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus | Q41670234 | ||
| Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients | Q43740101 | ||
| The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients | Q43945318 | ||
| Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients | Q44936481 | ||
| CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients | Q45413727 | ||
| Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome | Q45731345 | ||
| Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation. | Q45739439 | ||
| Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus | Q45759167 | ||
| Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression | Q45768710 | ||
| An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. | Q45789388 | ||
| Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients | Q46754641 | ||
| Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients | Q67249842 | ||
| Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival | Q83149379 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| liver transplantation | Q1368191 | ||
| P304 | page(s) | 730-740 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Liver Transplantation | Q15730498 |
| P1476 | title | Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience | |
| P478 | volume | 19 |
| Q53836055 | A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy. |
| Q48091829 | Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients |
| Q40389653 | Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy |
| Q95353303 | Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, He |
| Q50943935 | Lipid profile and cardiovascular risk factors in pediatric liver transplant recipients. |
| Q37622179 | Long term outcomes of pediatric liver transplantation according to age. |
| Q38265869 | Managing the challenge of PTLD in liver and bowel transplant recipients |
| Q26798306 | Neoplastic disease after liver transplantation: Focus on de novo neoplasms |
| Q38749102 | Pharmacoepidemiology of tacrolimus in pediatric liver transplantation. |
| Q104568675 | Post-transplant Lymphoproliferative Disorder in Recipient's Reconstructed Middle Hepatic Vein After Pediatric Living Donor Liver Transplant: A Case Report |
| Q37740522 | Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: experiences of 20 years in a single center. |
| Q42205086 | Relative EBV antibody concentrations and cost of standard IVIG and CMV-IVIG for PTLD prophylaxis in solid organ transplant patients |
| Q47599939 | Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort |
| Q45328713 | Two sides of the Epstein-Barr virus (EBV) coin: Long-term control of EBV after liver transplantation? |
Search more.